Gadoteric Acid Glucoamine Injection Obtains Drug Registration Certificate
March 27, 2025
Source: drugdu
39
On March 25, China Resources Double Crane announced that the company had received the Drug Registration Certificate for Gadoteric Acid Glucoamine Injection issued by the State Drug Administration. The drug is suitable for MRI examinations of diseases such as brain and spinal cord lesions and spinal lesions. The company started the research and development of generic drugs for the drug in May 2022, submitted an application for marketing authorization on June 15, 2023, and was approved for listing on March 18, 2025. As of the announcement date, the company's cumulative R&D investment in the drug was RMB 8.0652 million. In 2023, the total sales of Gadoteric Acid Glucoamine Injection in the domestic medical market and retail market were RMB 590 million, of which Jiangsu Hengrui Medicine had a market share of 89.46% and France Guerbet had a market share of 10.54%.
https://finance.eastmoney.com/a/202503253355613226.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- 6 domestic ADCs successfully go global April 3, 2025
- Medical equipment giant begins layoffs and factory closures April 3, 2025
- Cultivate “Innovation Skills” and Cultivate “Conscience Seedlings” April 3, 2025
- Zhifei Biotech’s adjuvanted trivalent influenza vaccine has obtained clinical trial approval, which is expected to further enrich the company’s virus vaccine varieties April 3, 2025
- Under the vaccine price war, the performance of the leading influenza vaccine company Hualan Vaccine in 2024 has stalled April 3, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
